Recommended

Teva close to API business sale
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

New EVP, Teva Global Operations appointed

0
SHARES

The new Executive Vice President of Teva Global Operations will bring “significant experience at every stage of the manufacturing and supply process” to his new role, the company asserted.

Teva manufacturing

[Credit: JHVEPhoto/Shutterstock.com].

Matthew Shields has been appointed as Executive Vice President of Teva Pharmaceutical Industries Ltd.’s manufacturing and supply division.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

His position within Teva Global Operations will commence on 3 June 2024. He will be part of the company’s Executive Leadership Team and be based at Teva’s US headquarters. Mr Shields stated that he is “honoured” to take on his new role.

Teva’s new appointment

Teva explained that with over 25 years of experience in the global biopharmaceutical and animal health industries, Mr Shields brings “significant experience at every stage of the manufacturing and supply process”.

Richard Francis, Teva’s President and CEO commented that he is “thrilled” with the new appointment, citing that Mr Shields will help the company to deliver its support to patients and healthcare systems globally.

Mr Shields will take over from Eric Drapé, who has been with the company for 11 years. This includes over four years as Executive Vice President, Global Operations, according to the pharmaceutical organisation.

Previous roles

MATTHEW SHIELDS EXECUTIVE VICE PRESIDENT, TEVA GLOBAL OPERATIONS

Matthew Shields appointed to Executive Vice President, Teva Global Operations (Photo: Business Wire)

In his most recent role, Mr Shields served as Senior Vice President for Animal Health Manufacturing for Merck, known as MSD Animal Health outside of the United States and Canada. This position involved overseeing end-to-end manufacturing, supply chain, procurement, and process development. He also led Specialty Care Manufacturing, Engineering, and Operational Excellence for Sanofi, Teva noted.

In his role as Global Head of Sanofi’s Specialty Care Manufacturing organisation, Mr Shields worked to facilitate successful launches of Dupixent® and Praluent®, Teva stated. He also oversaw the commissioning and startup of Sanofi’s first digitally enabled continuous manufacturing facility.

Early in his career, Mr Shields worked in various leadership roles in Operations at Amgen, Teva stated.

Mr Shields has an undergraduate degree in Chemical Engineering & Materials Science Engineering from the University of Connecticut. Teva added that he also holds an MBA from Bryant University in Rhode Island. At present, Mr Shields is a member of the board of the National Association of Manufacturers.

Share via
Share via